Unicycive Therapeutics (UNCY) Undisclosed Manufacturing Vendor Compliance Case

Attorneys review the case details to decide whether to proceed with a class action.

N.D. California

Court

3:26-cv-09559

Case number

12/09/2025

Class period Start

06/30/2026

Class period End

11/02/2026

Lead Plaintiff motion deadline

$UNCY investors filed a claim against Unicycive Therapeutics, Inc., its CEO, and its CFO for touting continued progress by its third-party manufacturing vendor in resolving FDA-cited deficiencies for its lead drug candidate, while failing to disclose that the Company had not inspected or audited the vendor's facility and lacked a reasonable basis to believe the deficiencies had been resolved.
After Unicycive disclosed that the FDA had issued a second Complete Response Letter citing the same third-party manufacturing deficiencies as its original 2025 rejection, and that the FDA had not even inspected the vendor's facility during the review, Unicycive's stock fell $3.01, or 39.1%, to close at $4.69 on June 30, 2026.
$UNCY investors can join this case to be notified about potential recovery.
Case Details:

Unicycive Therapeutics is a clinical-stage biotechnology company developing therapies for kidney disease, including its lead candidate oxylanthanum carbonate ("OLC"), an oral phosphate binder for patients with chronic kidney disease on dialysis. 

In June 2025, the FDA issued a Complete Response Letter on Unicycive's initial New Drug Application, citing compliance deficiencies at a third-party manufacturing vendor. Unicycive resubmitted the NDA in December 2025, telling investors the vendor had made "significant progress toward regaining FDA compliance."

Throughout the Class Period, in press releases and SEC filings including its FY2025 10-K and Q1 2026 10-Q, Unicycive continued to represent that the resubmission was based on "continued progress" by the vendor in resolving the FDA's cited deficiencies, and that it was on track for a June 29, 2026 PDUFA target action date. 

These statements omitted that Unicycive had not itself inspected or audited the vendor's facility for compliance, that it therefore lacked a reasonable basis to believe the deficiencies had actually been resolved, and that there was an undisclosed risk the FDA would require additional information about the vendor before approving OLC.

On June 30, 2026, before markets opened, Unicycive disclosed that the FDA had issued a second Complete Response Letter, citing the "same third-party manufacturing deficiencies" as the original 2025 CRL, and revealed that the FDA had not yet conducted its inspection of the vendor's facility during the resubmission review. 

On this news, Unicycive's stock fell $3.01, or 39.1%, to close at $4.69 per share on unusually heavy trading volume.

Based on these events, $UNCY investors filed a claim against Unicycive Therapeutics, Inc., alleging the Company:
Misrepresented the extent of progress made by its third-party manufacturing vendor in resolving FDA-cited compliance deficiencies
Failed to disclose that it had not independently inspected or audited the vendor's facility
Failed to disclose that it lacked a reasonable basis to believe the vendor's deficiencies had been resolved
Failed to disclose the risk that regulatory approval of OLC was reasonably likely to be delayed
Investors argue that had the truth about the vendor's compliance status been disclosed earlier, Unicycive's stock would not have traded at artificially inflated prices during the Class Period.

Case Type

US Securities Class Action

Case Status

Attorney Investigation

Alleged Offence

Misleading Statements,

Failure to Disclose

Suspected Party

Shareholder

Security Type

Stocks

Trade Direction

Long

Shock Event Date

06/30/2026

Filing date

09/03/2026

Lead Plaintiff Deadline

11/02/2026